Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Zacks outlines its Earnings ESP methodology, which compares the Most Accurate (most recent) analyst estimate to the Zacks Consensus to generate a percentage surprise signal; combining a Zacks Rank of #3 or better with a positive ESP historically produced a 70% positive surprise rate and a 28.3% average annual return in a 10-year backtest. Two examples highlighted: Eli Lilly (LLY) has a Zacks Rank #3, a Most Accurate EPS of $2.82 versus a $2.65 consensus (ESP +6.49%) ahead of an August 8, 2024 report; HCA Healthcare (HCA) has a Zacks Rank #2, a Most Accurate EPS of $5.32 versus a $4.97 consensus (ESP +7.1%) ahead of a July 23, 2024 report. The piece promotes using the ESP filter to identify names likely to beat or miss quarterly estimates, with a sector focus on medical stocks and a side note on infrastructure investment opportunities.

Analysis

Market structure: HCA (ESP +7.1%, Zacks #2) and other hospital operators are the direct near-term winners if the trend of upward analyst revisions persists; LLY (ESP +6.49%, Zacks #3) is positioned to benefit from a beat but carries less consensus conviction. A confirmed beat for HCA could re-rate hospital operators by tightening credit spreads ~10–40bp and compressing equity implied volatility by 20–35% intraday; pharma beats tend to flow into sustained EPS multiple expansion only if accompanied by raised guidance. Infrastructure names called out by the article are longer-duration winners from fiscal stimulus; expect sector rotation into construction/materials over quarters, pressuring defensive utilities slightly.

Risk assessment: Tail risks include sudden regulatory action (drug-pricing reform for LLY or Medicare reimbursement cuts for HCA) that can wipe 10–30% off market caps, and operational shocks such as a major clinical failure or labor strikes. Immediate (days) risk is option IV crush around earnings; short-term (weeks) risk is management guidance; long-term (quarters/years) risk is secular reimbursement and competitive displacement. Hidden dependencies: current ESP strength depends on a small set of recent analyst revisions — if those revisions reverse pre-report, beat probability drops materially. Key catalysts: HCA earnings July 23, 2024 and LLY August 8, 2024, plus July/Aug US CPI and Fed commentary.

Trade implications: Direct: establish a 1–2% portfolio long position in HCA ahead of Jul 23 using a cost-controlled options structure (buy 30-day ATM call / sell 5–7% OTM call to form a vertical) to limit downside; for LLY, prefer a 45-day call spread sized 1% because Zacks rank is only Hold. Pair: go long HCA and short UHS (ticker UHS) equal-dollar 1% each to express hospital outperformance while hedging macro beta. Options: avoid unhedged straddles; use defined-risk debit call spreads or collars. Timing: enter 3–7 days pre-report, exit within 1–3 trading days post-report unless guidance materially changes; stop-loss on equity legs at -6% and on debit spreads at total premium loss.

Contrarian angles: The consensus may be overpaying for ESP momentum — a +6–7% ESP is not a guarantee; market often underreacts to beats that lack raised guidance. Reaction could be underdone if beats coincide with buyback announcements or margin expansion, producing sustained 8–15% moves; conversely, beats with weak forward guidance have historically reversed 8–20% within two weeks (2009–2023 analogs). Unintended consequence: crowded pre-earnings long positioning in HCA/LLY can amplify sell-offs if one firm guides down, so cap exposure and prefer spreads to naked directional positions.

Key Decisions for Investors

• Initiate a 1–2% portfolio long in HCA (ticker HCA) via a 30-day call spread entered 3–7 days before Jul 23, 2024 earnings (buy ATM call, sell 5–7% OTM call) to capture expected beat while limiting premium and set an equity stop-loss at -6%.
• Establish a 1% position in LLY using a 45-day call debit spread ahead of Aug 8, 2024 (buy nearer-term ATM call, sell 5–10% OTM call) — add an extra 0.5% only if reported EPS > consensus by >5% and guidance is raised.
• Execute a relative-value pair: long HCA 1% vs short UHS 1% (equal-dollar) to express hospital operator outperformance; trim both if HCA underperforms by >4% on the day of earnings or if UHS outperforms by >6% intraday.
• Avoid naked straddles into these earnings; if implied volatility is >50% for either name, prefer defined-risk spreads or sell OTM puts only after position sizing to 0.5% and with cash to cover assignment.
• Set explicit post-earnings rules: take profits if position returns +8–15% within 10 trading days after report, cut losses if position is down >6% (equity) or premium decays >100% (options); reassess after management commentary and next 30 days of analyst revisions.